Team
Kieran Murphy MB BAO BCH FRCPC FSIR
Founder & Chief Science Officer
Dr Kieran Murphy is a physician and interventional neuroradiologist at Toronto Western Hospital in Toronto, Ontario. Dr Murphy is a pioneering clinician, translational researcher, and inventor, who has authored 176 peer reviewed publications and filed over 60 patents. He graduated from the Royal College of Surgeons in Dublin, Ireland, in 1986, completed his Radiology residency and Neuroradiology fellowship at the University of Michigan, Ann Arbor, and his Interventional Neuroradiology fellowship at University of Geneva. Prior to arriving in Toronto, he led the division of Interventional Neuroradiology at Johns Hopkins for 10 years.
Dr Murphy has filed 60 patents on new medical devices, pioneering new routes, techniques and approaches to complex spine, neurovascular and CSF pathologies. He has founded eight medical device companies, authored over 170 peer reviewed publications, published several textbooks and mentored over 100 Undergraduate, Masters, and PhD candidates, medical students, residents, fellows and staff physicians.
He launched and led UHN's International Health Care Program, successfully negotiating with the Kuwait, Bahrain, Qatar, and Saudi governments. From 2012-2016 he was Director of Clinical Faculty at the Techna Research Institute and has been heavily involved in developing a culture of innovation and entrepreneurial behaviour in the Techna and UHN faculty.
Dr Murphy’s current focus is on spine augmentation, radiofrequency ablation of bone metastatic disease, ozone in disk herniations, antioxidant use in radiation injury reduction, and global medical education. His hobbies include medical device development, historic airplanes, race car driving and taking things apart. He was awarded the Society of Interventional Radiology Innovator of the Year award in 2015 and was nominated for the 2016 Manning Innovation award. He received the 2019 American Society of Vascular Interventional Technology award for innovation and mentorship. He is Senior Technology Advisor to TVM private Equity based in Dubai, and Shore capital based in Chicago.
William (Bill) Attinger
CEO
For the past 34 years, Bill has been a leader and innovator in growing, financing, and developing early stage and high-growth middle-market companies. Through his background in finance, private equity, venture capital and investment banking, he brings “by the numbers” expertise in quantitatively evaluating companies and helping them manage their growth and exit opportunities. As a founder or co-founder of six companies and an adviser to dozens more, he has accumulated a depth of practical hands-on operational experience across a breadth of industries and functional disciplines.
As an investment banker for Morgan Stanley in the early 1990’s in New York and Silicon Valley, Bill focused on healthcare finance, serving some of the largest teaching hospitals and healthcare systems in the US. He structured more than $1 billion of publicly offered securities using innovative, derivative-based financing structures, and his derivative research has been published in the Financial Analysts Journal. After his tenure as an investment banker, Bill launched multiple companies in a variety of industry verticals as a venture-backed founder or co-founder, including internet, mobile, consumer products, industrial, manufacturing and health / wellness.
For the past decade, Bill has served as a Managing Partner and Investment Strategist for investing partnerships under the Global Trust / Global Community Capital umbrella, and within these partnerships, capitalized over 30 companies in a breadth of industries, including AI, supply chain, apparel, medical devices, public safety tech, film and music, travel, commercial real estate, extraterrestrial ventures and more. In 2018, Bill also partnered with Tony Forstmann at Forstmann & Co. to develop new ventures in digital currencies, a tokenized trading exchange, commerce software and carbon-reduction green technologies.
Mr. Attinger earned his Bachelor’s Degree in Economics and his Master’s Degree in Finance from the University of Alabama.
Bryan Sigler
COO
With over 30 years of leadership in healthcare, medical devices, and regulated sectors, Bryan brings a proven track record of operational excellence and regulatory expertise to high-stakes environments. As Chief Operating Officer at Control Flo Medical, LLC, he spearheads the De Novo FDA application process for an innovative medical device, overseeing compliance, manufacturing agreements, and shareholder relations with precision. Previously, as Chief Development Officer at Sanctuary Systems, LLC, he served as a government agency liaison and managed international contract negotiations, ensuring strict adherence to regulatory standards.
Bryan’s career also includes impactful roles such as Production and Operations Manager for a high-performance automotive project under license from Carroll Shelby at a Las Vegas facility, showcasing his versatility in regulated industries. His extensive healthcare administration experience spans leadership positions like Director of the Chemical Dependency Center at Baytown Medical Center and Instructor of Health Administration at Florida Atlantic University, deepening his understanding of complex regulatory frameworks.
Holding an MBA from Louisiana Tech University and 66 doctoral hours in Administration-Health Services from the University of Alabama, Birmingham, Bryan combines strategic vision with hands-on expertise. His ability to navigate intricate regulatory landscapes and drive operational success makes him a valued leader in any highly regulated field.
Scientific Advisory Board
John Kaufman, MD, MS
Dr. Kaufman is director of the Dotter Institute and past president of the Society of Interventional Radiology. His clinical interests include aortic aneurysms, venous diseases, vascular malformations, and image guide treatment of liver cancers and uterine fibroids. He is also actively involved in clinical research in these areas.
He has authored or co-authored more than 200 publications including five textbooks. He is co-editor of the quarterly review journal Techniques in Vascular and Interventional Radiology and Associate Editor for the journal CardioVascular and Interventional Radiology. He has been honored as a Gold Medalist of the Society of Interventional Radiology, a Distinguished Fellow of the Cardiovascular and Interventional Radiology Society of Europe, and a Distinguished Alumnus of the Boston University School of Medicine.
Michael Dake, MD
Dr Michael Dake is a graduate of Harvard College and Baylor College of Medicine, where he completed an internship, residency and chief residency in internal medicine. He is board certified in internal medicine, pulmonary disease, diagnostic radiology, and vascular and interventional radiology.
Dr Dake has an international reputation for revolutionary work in improving vascular health to help treat debilitating diseases. He has published more than 300 peer-reviewed articles and more than 100 book chapters. His publications in Nature Medicine have been cited more than 1,000 times, and his papers in the New England Journal of Medicine have been referenced more than 1,500 times. Overall, the impact of Dr Dake's contributions to the medical literature have earned more than 30,000 citations, which puts him among the top scientists in his field. He holds 31 U.S. patents and has founded five companies.
Lindsay Machan, MD
Dr. Machan is an interventional radiologist at the Vancouver Hospital and Associate Professor of Radiology at the University of British Columbia. His professional interests include endovascular vein therapy and local therapy of restenosis. He is co-founder of Angiotech Pharmaceuticals, a company which developed and licensed the paclitaxel coated stent, and Ikomed Technologies which is developing methods for reducing radiation dose during fluoroscopy.
Dr. Machan is a found of CIRA (Canadian Interventional Radiology Association), the co-author or Interventional Procedures, the largest selling interventional textbook worldwide, and sits on many commercial and scientific advisory boards for medical companies across Canada and the U.S. As well as being an active angel investor, he is heavily involved as a clinical practitioner, researcher and teacher at Vancouver Hospital, and has authored over 140 patents.